PAR-25-107-Full-Announcement.html

This document is a Notice of Funding Opportunity (NOFO) for the Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R01 Clinical Trial Not Allowed) federal grant opportunity. The National Cancer Institute (NCI) is soliciting grant applications to utilize bacteria, archaebacteria, bacteriophages, or other non-oncolytic viruses and their natural products to study the underlying mechanisms of the complex interactions between microorganisms, tumors, and the immune system, and to explore their clinical potential for cancer imaging, therapeutics, or diagnostics. Projects can focus on using microorganisms as anti-tumor agents, as activators of anti-tumor immunity, or as delivery vehicles. This funding opportunity supports basic mechanistic and preclinical studies in cell culture and animal models. Eligible applicants include tribal governments, higher education institutions, small businesses, nonprofits, and others. The funding is provided under CFDA numbers 93.395 Cancer Treatment Research, 93.121 Oral Diseases and Disorders Research, and 93.396 Cancer Biology Research, with the Department of Health and Human Services National Institutes of Health as the federal agency.